 - Adults with established, pathologically confirmed diagnoses of newly diagnosed, poor-risk Acute Myeloid LeukemiaAML including de novo and secondary Acute Myeloid Leukemias but excluding newly diagnosed acute progranulocytic leukemia APL, M3 will be considered eligible for study 